MAPT and cancer: Dysregulated PPIs whereone partner is disordered have been implicated in various diseases,including cancer (e.g., p53, MYC), neurodegenerative disorders (e.g.,α-synuclein, tau), etc. A systematic approach for targetingsuch interactions is not yet available.